VA-DXC-TECHNOLOGY
15.9.2021 10:02:09 CEST | Business Wire | Press release
DXC Technology (NYSE: DXC) and Lenovo today announced a collaboration with visionary robotics scientist Dr. Peter Scott-Morgan and his philanthropic foundation to develop ambitious assistive technology solutions by integrating the latest hardware, software, and artificial intelligence (AI) technologies to empower people with disabilities, illnesses, and other challenging conditions.
Scott-Morgan, known as the “world’s first human cyborg", is pushing technology to extend and enrich lives. He was diagnosed with motor neuron disease (MND) – also known as amyotrophic lateral sclerosis (ALS) – in 2017. When the first symptoms emerged, Scott-Morgan began exploring ways to upend the typical disease progression through his belief in the limitless potential of technology. Scott-Morgan’s vision is to: “Make the vulnerable safe, the powerless strong, the unfulfilled thrive.”
“The bedrock of our collaboration is a belief in the untapped potential of technology to unleash your dreams - whatever you are, whatever your background, whatever your circumstances, whatever your ambitions,” Scott-Morgan said. Initially told by doctors he had only two years to live, Scott-Morgan has a mantra: “Add hope with AI and Robotics!”
DXC and Lenovo – alongside a team of volunteers and leading technologists – will provide hardware, software support, integration, and artificial intelligence expertise. Key initiatives include:
- Developing autonomous, self-driving wheelchairs to navigate homes and beyond;
- Preserving personality with an avatar that renders quickly in photo-realistic detail;
- Leveraging augmented reality (AR) as a user interface controlled with only eye movements;
- Accelerating the generation and customization of emotionally expressive digital voices; and
- Embedding smart technology throughout a family home to enhance the life of all its occupants.
In addition to developing custom solutions, Lenovo has donated computing equipment for Scott-Morgan’s home-office. Calvin Crosslin, Lenovo’s Chief Diversity Officer and President of the Lenovo Foundation said: “We have a responsibility to make powerful technology as accessible as possible and create new opportunities. This is precisely why we rally behind the idea of smarter technology for all, and I am grateful to Dr. Scott-Morgan for inviting us to collaborate and share some small part of his extraordinary vision.”
DXC will act as technology integrator. Deploying capabilities from the Enterprise Technology Stack, DXC will bring technology know-how and experience to ensure seamless and secure integration across infrastructure, applications, analytics, and engineering solutions.
“Peter is an astonishing inspiration,” said Steve Turpie, President, EMEA at DXC. “The DXC team will offer consulting and support to define requirements, the target architecture, and the technology roadmap. Specifically, they will enable the functions for eye tracking, virtual keyboards, speech, and avatar performance. Peter, with the Foundation, has a tireless passion to challenge our thinking on how technology can be used to enhance people’s lives and society.”
Learn more about Dr. Peter Scott-Morgan, including his background, ongoing research, and opportunities to get involved through The Scott-Morgan Foundation .
“I applied a lifetime of research to rewrite my own future - an extraordinarily lucky break! But far more important, we’ve now the chance to rewrite the future for millions - eventually billions - by applying the lessons learned to make the vulnerable safe, the powerless strong, the unfulfilled thrive. I wanted a way to break free of my suddenly inadequate body, to overcome a devastating diagnosis and reimagine what ‘terminal disease’ could mean. But we can help everyone who feels disadvantaged. They can rise like a phoenix! With extraordinary support from my husband Francis, countless kind and brilliant collaborators, and technology leaders like DXC and Lenovo, I find the once-dark future incredibly bright.”
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services across the Enterprise Technology Stack to drive new levels of performance, competitiveness, and customer experience. Learn more about how we deliver excellence for our customers and colleagues at DXC.com .
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services, and software) millions of customers every day and together create a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .
About Lenovo Tech World 2021 and Dr Peter Scott-Morgan
Scott-Morgan joined Lenovo at its Tech World 2021 event on September 8 to speak with Thorsten Stremlau, Lenovo’s director of strategic enterprise consulting, about their shared goals of delivering smarter technology for all.
“I am deeply humbled to work with Peter, an absolutely brilliant scientist and inspiring human,” said Stremlau, who is leading Lenovo’s efforts. “We focus a lot on increasing accessibility and diversity at Lenovo , and this is a singular opportunity to ensure our innovation makes a real difference – for both Peter and, I hope, many others.”
About other partners supporting The Scott-Morgan Foundation
Other key collaborators already working with Scott-Morgan on this initiative include Matthew Aylett of CereProc, Amanda Darby of Optimize3D at Pinewood Studios, and Ari Shapiro of Embody Digital.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005415/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom